Investment Attraction
Invest in Manchester
Full Credential Description
Seda Group, a pioneering life sciences company specializing in pharmaceutical development and clinical manufacturing services, faced the challenge of expanding its operational capabilities to meet the growing demand for advanced pharmaceutical services in the UK. To address this, Seda made a significant investment of £8 million to establish a new Clinical Manufacturing Services (CMS) facility at Cheadle Royal Business Park, which is set to become fully operational in early 2025. This facility is expected to create up to 100 high-skilled jobs over the next five years, with more than half of its projected revenue anticipated to come from international clients.
The tailored solution provided by Seda involved leveraging the strategic advantages of Greater Manchester's life sciences ecosystem, which includes a talented workforce and excellent connectivity. The new facility will enhance Seda's capabilities in Good Manufacturing Practice (GMP) manufacturing, testing, and supply of investigational medicinal products for clinical studies. This expansion not only positions Seda to better serve its clients but also reinforces Greater Manchester's status as a key player in the UK's life sciences sector.
MIDAS played a crucial role in supporting Seda's strategic expansion by facilitating connections with potential partners and collaborators, including universities and research centers. They provided valuable information and research about the Greater Manchester area, organized familiarization visits, and offered PR and marketing support, as well as guidance on accessing grants and funding. This comprehensive support from MIDAS has been instrumental in helping Seda establish and grow within the region's thriving bio ecosystem, ultimately contributing to advancements in health and wellbeing.